Skip to main content

Table 1 Baseline characteristics of MC-CAP and SP-CAP patients

From: Clinical characteristics of community-acquired pneumonia due to Moraxella catarrhalis in adults: a retrospective single-centre study

 

MC-CAP (%)

SP-CAP (%)

P valuea

Number of patients

134

130

 

Background

 Age: mean ± SD

75.2 ± 15.6

66.2 ± 17.4

< 0.01

 Gender (M/F)

72/62

64/66

0.46

 Body mass indexb, mean ± SD

23.6 ± 5.6

22.4 ± 3.5

< 0.05

 Ever smoker

55 (41)

42 (32.3)

0.14

Underlying pulmonary disease

 Asthma

51 (38.1)

25 (19.2)

< 0.01

 Bronchiectasis

56 (41.8)

22 (16.9)

< 0.01

 Chronic obstructive pulmonary disease (COPD)

35 (26.1)

26 (20)

0.24

 Interstitial pneumonia

6 (4.5)

1 (0.8)

0.06

 Lung cancer

6 (4.5)

4 (3.1)

0.55

 Old tuberculosis

15 (11.2)

10 (7.7)

0.33

 Under home oxygen therapy

16 (11.9)

4 (3.1)

< 0.01

 Usage continuous positive airway pressure therapy

6 (4.5)

1 (0.8)

0.06

Systemic underlying disease

 Cerebrovascular disease

7 (5.2)

4 (3.1)

0.38

 Chronic heart failure

41 (30.6)

18 (13.8)

< 0.01

 Chronic kidney disease

15 (11.2)

3 (2.3)

< 0.01

 Collagen disease

3 (2.2)

0 (0)

0.08

 Diabetes mellitus

23 (17.2)

14 (10.8)

0.13

 Hypertension

64 (47.8)

48 (36.9)

0.07

 Malignancy

15 (11.2)

8 (6.2)

0.14

Severity

 CURB-65

  Mild

96 (71.6)

103 (79.2)

0.15

  Moderate

32 (23.9)

22 (16.9)

0.16

  Severe

6 (4.5)

5 (3.8)

0.79

 qSOFA

   ≥ 2

5 (3.7)

8 (6.2)

0.36

Clinical manifestation

 High fever (≥38 °C)

50 (37.3)

80 (61.5)

< 0.01

 Systolic blood pressure ≤ 100 mmHg

3 (2.2)

11 (8.5)

< 0.05

 Shaking chill

8 (6)

26 (20)

< 0.01

 COPD exacerbation

10/35 (28.6)

5/26 (19.2)

0.4

 Asthma attack

24/51 (47)

13/25 (52)

0.68

Laboratory data

 White blood cellc, mean ± SD

11,451 ± 4556

12,543 ± 5118

< 0.05

 C-reactive proteind, mean ± SD

8.2 ± 7.4

9.1 ± 7.6

0.17

 Serum albumine, mean ± SD

3.6 ± 0.5

3.7 ± 0.5

0.21

 Positive for influenza virus rapid test

4 (3)

19 (14.6)

< 0.01

Blood culture

 Positive

1 (0.7)

2 (1.5)

0.54

Initial treatment

 Penicillin (ABPC, ABPC/SBT, AMPC, or AMPC/CVA)

70 (52.2)

71 (54.6)

0.69

 Cephalosporin (CTM, CTRX, CTX, or CMZ)

48 (35.8)

51 (39.2)

0.57

 Macrolides (AZM)

8 (6)

6 (4.6)

0.62

 Tetracyclines (MINO)

5 (3.7)

0 (0)

< 0.05

 Fluoroquinolones (LVFX)

2 (1.5)

1 (0.8)

0.57

Outcome

 Hospitalised patients

79 (59)

76 (58.4)

0.93

 Length of antibiotic treatment, mean ± SD

6.8 ± 2.2

7.1 ± 2.3

0.17

 Length of hospital stay, mean ± SD

9.2 ± 4.7

8.6 ± 3.0

0.19

 In-hospital mortality

0

0

–

  1. Abbreviations: COPD chronic obstructive pulmonary disease, SD standard deviation, ABPC ampicillin, ABPC/SBT ampicillin sulbactam, AMPC amoxicillin, AMPC/CVA amoxicillin clavulanate, CTM cefotiam, CTRX ceftriaxone, CTX cefotaxime, CMZ cefmetazole, AZM azithromycin, MINO minocycline, LVFX levofloxacin
  2. aStatistical differences between MC-CAP and SP-CAP were evaluated by Pearson’s χ2 or Fisher’s exact test for categorical variables and Mann-Whitney U test for continuous variables
  3. bNumber of patients was 108 in MC-CAP and 93 in SP-CAP
  4. cNumber of patients was 118 in MC-CAP and 113 in SP-CAP
  5. dNumber of patients was 117 in MC-CAP and 109 in SP-CAP
  6. eNumber of patients was 98 in MC-CAP and 91 in SP-CAP
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us